{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:52:47Z","timestamp":1790232767212,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM113832"],"award-info":[{"award-number":["GM113832"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL068878"],"award-info":[{"award-number":["HL068878"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL134569"],"award-info":[{"award-number":["HL134569"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS091555"],"award-info":[{"award-number":["NS091555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["13SDG17230049"],"award-info":[{"award-number":["13SDG17230049"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["15PRE25090050"],"award-info":[{"award-number":["15PRE25090050"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["15SDG24470155"],"award-info":[{"award-number":["15SDG24470155"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16POST27760002"],"award-info":[{"award-number":["16POST27760002"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19PRE34400017"],"award-info":[{"award-number":["19PRE34400017"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["T32 GM008353"],"award-info":[{"award-number":["T32 GM008353"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["T32-HL125242"],"award-info":[{"award-number":["T32-HL125242"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015891","name":"Animal Health Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jconrel.2020.11.016","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T15:37:36Z","timestamp":1605109056000},"page":"361-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport"],"prefix":"10.1016","volume":"329","author":[{"given":"Wenmin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Eugene","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2020.11.016_bb0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-015-3827-x","article-title":"LXR\u03b1 improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes","volume":"59","author":"Cannon","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1074\/jbc.M210208200","article-title":"Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis","volume":"278","author":"Cao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.21775\/cimb.022.041","article-title":"Liver X receptors and their agonists: targeting for cholesterol homeostasis and cardiovascular diseases","volume":"22","author":"Ma","year":"2017","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phrs.2013.03.008","article-title":"Liver X receptors: emerging therapeutic targets for Alzheimer\u2019s disease","volume":"72","author":"Sodhi","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.016_bb0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbalip.2010.05.015","article-title":"Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity","volume":"1801","author":"Aye","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"36","key":"10.1016\/j.jconrel.2020.11.016_bb0030","doi-asserted-by":"crossref","first-page":"28240","DOI":"10.1074\/jbc.M003337200","article-title":"Sterol-dependent transactivation of theABC1 promoter by the liver X receptor\/retinoid X receptor","volume":"275","author":"Costet","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.016_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.jconrel.2020.11.016_bb0040","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":"Synthetic LXR ligand inhibits the development of atherosclerosis in mice","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1194\/jlr.M800376-JLR200","article-title":"Synthetic LXR agonist attenuates plaque formation in apoE\u2212\/\u2212mice without inducing liver steatosis and hypertriglyceridemia","volume":"50","author":"Kratzer","year":"2009","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","article-title":"LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE* 3Leiden mice: time course and mechanisms","volume":"50","author":"Verschuren","year":"2009","journal-title":"J. Lipid Res."},{"issue":"37","key":"10.1016\/j.jconrel.2020.11.016_bb0055","doi-asserted-by":"crossref","first-page":"34182","DOI":"10.1074\/jbc.M204887200","article-title":"Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles","volume":"277","author":"Grefhorst","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2020.11.016_bb0060","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1194\/jlr.M500116-JLR200","article-title":"Synthetic LXR agonists increase LDL in CETP species","volume":"46","author":"Groot","year":"2005","journal-title":"J. Lipid Res."},{"issue":"22","key":"10.1016\/j.jconrel.2020.11.016_bb0065","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"Schultz","year":"2000","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.016_bb0070","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/MCB.21.9.2991-3000.2001","article-title":"Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter","volume":"21","author":"Yoshikawa","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2020.11.016_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI38911","article-title":"LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression","volume":"120","author":"Feig","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.jconrel.2020.11.016_bb0080","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1194\/jlr.M400257-JLR200","article-title":"Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor","volume":"45","author":"Quinet","year":"2004","journal-title":"J. Lipid Res."},{"issue":"44","key":"10.1016\/j.jconrel.2020.11.016_bb0085","doi-asserted-by":"crossref","first-page":"E6731","DOI":"10.1073\/pnas.1609629113","article-title":"Immune cell screening of a nanoparticle library improves atherosclerosis therapy","volume":"113","author":"Tang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2020.11.016_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","article-title":"T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice","volume":"536","author":"Terasaka","year":"2003","journal-title":"FEBS Lett."},{"issue":"20","key":"10.1016\/j.jconrel.2020.11.016_bb0095","doi-asserted-by":"crossref","first-page":"1700313","DOI":"10.1002\/adhm.201700313","article-title":"Targeted nanotherapeutics encapsulating liver x receptor agonist gw3965 enhance antiatherogenic effects without adverse effects on hepatic lipid metabolism in Ldlr\u2212\/\u2212 mice","volume":"6","author":"Yu","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0100","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1038\/ncomms4065","article-title":"A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation","volume":"5","author":"Duivenvoorden","year":"2014","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2011.05.029","article-title":"Antiatherogenic effects of newly developed apolipoprotein AI mimetic peptide\/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits","volume":"218","author":"Iwata","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport","volume":"36","author":"Fielding","year":"1995","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.016_bb0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcph.194","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.016_bb0120","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ahj.2015.01.008","article-title":"The effect of an apolipoprotein AI\u2013containing high-density lipoprotein\u2013mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study","volume":"169","author":"Hovingh","year":"2015","journal-title":"Am. Heart J."},{"issue":"17","key":"10.1016\/j.jconrel.2020.11.016_bb0125","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.016_bb0130","first-page":"e19","article-title":"P105 single-dose tolerability, pharmacokinetics, and cholesterol mobilization in Hdl-c fraction following intravenous administration of Etc-642, a 22-mer Apoa-i analogue and phospholipids complex, in atherosclerosis patients","volume":"24","author":"Miles","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"46","key":"10.1016\/j.jconrel.2020.11.016_bb0135","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.jconrel.2020.11.016_bb0140","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.jconrel.2020.11.016_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.12.021","article-title":"Synthetic high-density lipoprotein-mediated targeted delivery of liver X receptors agonist promotes atherosclerosis regression","volume":"28","author":"Guo","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2020.11.016_bb0150","unstructured":"Dasseux, J.-L., A.S. Schwendeman, and L. Zhu, Apolipoprotein AI mimics. 2013, Patent US9981008B2."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0155","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.2147\/IJN.S140591","article-title":"Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma","volume":"12","author":"Kuai","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"10","key":"10.1016\/j.jconrel.2020.11.016_bb0160","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1172\/JCI79048","article-title":"Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production","volume":"125","author":"Guo","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.surg.2015.08.023","article-title":"Synthetic high-density lipoprotein nanoparticles: a novel therapeutic strategy for adrenocortical carcinomas","volume":"159","author":"Subramanian","year":"2016","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.016_bb0170","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.nano.2017.04.009","article-title":"Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting","volume":"13","author":"Tang","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.11.016_bb0175","series-title":"Apolipoprotein Mimetics in the Management of Human Disease","first-page":"29","author":"Anantharamaiah","year":"2015"},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.016_bb0180","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","article-title":"High-density lipoproteins: nature\u2019s multifunctional nanoparticles","volume":"10","author":"Kuai","year":"2016","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.016_bb0185","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/CIRCRESAHA.116.308685","article-title":"Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity","volume":"119","author":"Didichenko","year":"2016","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acs.molpharmaceut.7b00734","article-title":"Effect of synthetic high density lipoproteins modification with polyethylene glycol on pharmacokinetics and pharmacodynamics","volume":"15","author":"Li","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1194\/jlr.M071043","article-title":"Influence of route of administration and lipidation of apolipoprotein AI peptide on pharmacokinetics and cholesterol mobilization","volume":"58","author":"Tang","year":"2017","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.016_bb0200","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1194\/jlr.M060285","article-title":"The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties","volume":"56","author":"Schwendeman","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2014.09.009","article-title":"Protein corona change the drug release profile of nanocarriers: the \u201coverlooked\u201d factor at the nanobio interface","volume":"123","author":"Behzadi","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2003.10.001","article-title":"Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth","volume":"205","author":"Ichikawa","year":"2004","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.jconrel.2020.11.016_bb0220","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nnano.2013.181","article-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology","volume":"8","author":"Tenzer","year":"2013","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.016_bb0230","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","article-title":"CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects","volume":"34","author":"Wright","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.016_bb0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.ATV.0000150044.84012.68","article-title":"Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists","volume":"25","author":"Levin","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.016_bb0240","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/adhm.201300688","article-title":"Development of therapeutic polymeric nanoparticles for the resolution of inflammation","volume":"3","author":"Gadde","year":"2014","journal-title":"Adv. Healthc. Mater."},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/adhm.201400337","article-title":"Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis","volume":"4","author":"Zhang","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2020.11.016_bb0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chemphyslip.2017.02.006","article-title":"Role of the liver X receptors in skin physiology: putative pharmacological targets in human diseases","volume":"207","author":"Ouedraogo","year":"2017","journal-title":"Chem. Phys. Lipids"},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.016_bb0255","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1167\/iovs.14-15612","article-title":"Activation of liver X receptor protects inner retinal damage induced by N-methyl-D-aspartate","volume":"56","author":"Zheng","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.016_bb0260","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants","volume":"49","author":"Katz","year":"2009","journal-title":"J. Clin. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:55:43Z","timestamp":1759161343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920306659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":51,"alternative-id":["S0168365920306659"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}